CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on chimeric engulfment receptor, or CER, T-cell immunotherapies for the treatment of hematologic malignancies and solid tumors. The company went public through a merger with Phoenix Biotech Acquisition Corp. (PBAX), a blank-check company sponsored by Phoenix Biotech Sponsor, LLC that completed its IPO in 2021. The 10-Q filed on May 13, 2022, under accession number 0001193125-22-150082, represents a quarterly disclosure from the combined public entity as it advances its pipeline in the oncology and cell therapy sector. For full filing history, sponsor details, and deal analytics on CERO and hundreds of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.